Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | GLA | P06280 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL271899 | 0.85 | TP53 (0.64) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL2030599 | 0.84 | ALDH1A1 (0.70) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL9614163 | 0.84 | ALDH1A1 (0.48) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL3837959 | 0.82 | ALDH1A1 (0.68) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL8553241 | 0.81 | SMN1; SMN2 (0.49) | ALDH1A1GLATSHRKMT2AHTT | |
| SCHEMBL16110560 | 0.81 | MEN1 (0.44) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL308738 | 0.81 | ALDH1A1 (0.66) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL7363268 | 0.81 | ALDH1A1 (0.66) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL2032136 | 0.81 | NPC1 (0.66) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL3364487 | 0.81 | ALDH1A1 (0.66) | ALDH1A1GLATSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1212056-B1 | METHODS AND COMPOSITIONS FOR BISUBSTRATE INHIBITORS OF ACETYLTRANSFERASES | US GOV HEALTH & HUMAN SERV (US) | 2005-12-07 | — | — | EP | claimed |
| EP-1212056-A1 | METHODS AND COMPOSITIONS FOR BISUBSTRATE INHIBITORS OF ACETYLTRANSFERASES | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2002-06-12 | — | — | EP | claimed |
| US-20020002144-A1 | Methods and compositions for bisubstrate inhibitors of acetyltransferases | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2002-01-03 | — | — | US | claimed |
| WO-2001012185-A1 | METHODS AND COMPOSITIONS FOR BISUBSTRATE INHIBITORS OF ACETYLTRANSFERASES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-02-22 | — | — | WO | claimed |
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA (SE) | 2010-08-26 | — | — | US | disclosed |
| EP-1212056-B1 | METHODS AND COMPOSITIONS FOR BISUBSTRATE INHIBITORS OF ACETYLTRANSFERASES | US GOV HEALTH & HUMAN SERV (US) | 2005-12-07 | — | — | EP | disclosed |
| CN-1146566-C | 2-aryl-8-oxodihydropurine derivatives, process for producting same, medicinal conty. same, and intermediates thereof | �ձ���ҩ��ʽ���� | 2004-04-21 | — | — | CN | disclosed |
| EP-1036794-B1 | 2-ARYL-8-OXODIHYDROPURINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, MEDICINAL COMPOSITIONS CONTAINING THE SAME, AND INTERMEDIATES THEREOF | DAINIPPON PHARMACEUTICAL CO (JP) | 2003-08-27 | — | — | EP | disclosed |
| EP-0826673-B1 | ACETAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL COMPOSITION CONTAINING THE SAME | DAINIPPON PHARMACEUTICAL CO (JP) | 2002-11-20 | — | — | EP | disclosed |
| EP-1212056-A1 | METHODS AND COMPOSITIONS FOR BISUBSTRATE INHIBITORS OF ACETYLTRANSFERASES | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2002-06-12 | — | — | EP | disclosed |
| US-6372740-B1 | NERVOUS SYSTEM DISORDERS, ANTIEPILEPTIC AGENTS AND ANTIDEPRESSANTS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2002-04-16 | — | — | US | disclosed |
| US-20020002144-A1 | Methods and compositions for bisubstrate inhibitors of acetyltransferases | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2002-01-03 | — | — | US | disclosed |
| EP-0672037-B1 | 1,4-BENZODIAZEPINE DERIVATIVES AND THEIR USE AS CCK-MODULATORS | GLAXO GROUP LTD (GB) | 1998-07-08 | — | — | EP | disclosed |
| EP-0826673-A1 | ACETAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND MEDICINAL COMPOSITION CONTAINING THE SAME | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1998-03-04 | — | — | EP | disclosed |
| US-5569654-A | ADMINISTERING AS ANTAGONISTS OF GASTRIN AND CHOLECYSTOKININ | GLAXO GROUP LIMITED (GB) | 1996-10-29 | — | — | US | disclosed |
| EP-0672037-A1 | 1,4-BENZODIAZEPINE DERIVATIVES AND THEIR USE AS CCK-MODULATORS | GLAXO GROUP LIMITED (GB) | 1995-09-20 | — | — | EP | disclosed |
| WO-1994013648-A1 | 1,4-BENZODIAZEPINE DERIVATIVES AND THEIR USE AS CCK-MODULATORS | GLAXO GROUP LIMITED (GB) | 1994-06-23 | — | — | WO | disclosed |
| CN-1074216-A | Urea derivative | GLAXO GROUP LTD (GB) | 1993-07-14 | — | — | CN | disclosed |
| WO-1993008175-A1 | BENZODIAZEPINE DERIVATIVES AS ANTAGONISTS OF GASTRIN AND/OR CHOLECYSTOKININ | GLAXO GROUP LIMITED (GB) | 1993-04-29 | — | — | WO | disclosed |
| EP-0538945-A1 | Benzodiazepine derivatives, and their use as antagonists of gastrin and/or cholecystokinin | GLAXO GROUP LIMITED (GB) | 1993-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | ALDH1A1 948/4885GLA 3414/4885TSHR 2601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.